SG Americas Securities LLC Purchases New Holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

SG Americas Securities LLC acquired a new stake in Tenaya Therapeutics, Inc. (NASDAQ:TNYAGet Rating) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 10,538 shares of the company’s stock, valued at approximately $59,000.

Other large investors have also recently added to or reduced their stakes in the company. Amalgamated Bank acquired a new position in Tenaya Therapeutics in the 1st quarter valued at approximately $29,000. California State Teachers Retirement System increased its stake in Tenaya Therapeutics by 62.2% in the 1st quarter. California State Teachers Retirement System now owns 12,208 shares of the company’s stock valued at $144,000 after buying an additional 4,682 shares during the period. American International Group Inc. increased its stake in Tenaya Therapeutics by 91.8% in the 1st quarter. American International Group Inc. now owns 14,195 shares of the company’s stock valued at $167,000 after buying an additional 6,794 shares during the period. Bank of America Corp DE increased its stake in Tenaya Therapeutics by 24.2% in the 1st quarter. Bank of America Corp DE now owns 18,305 shares of the company’s stock valued at $216,000 after buying an additional 3,566 shares during the period. Finally, MetLife Investment Management LLC increased its stake in Tenaya Therapeutics by 219.7% in the 1st quarter. MetLife Investment Management LLC now owns 18,722 shares of the company’s stock valued at $221,000 after buying an additional 12,865 shares during the period. Institutional investors and hedge funds own 87.40% of the company’s stock.

Tenaya Therapeutics Trading Down 21.6 %

NASDAQ:TNYA opened at $2.50 on Friday. Tenaya Therapeutics, Inc. has a 1 year low of $1.73 and a 1 year high of $22.87. The firm’s fifty day simple moving average is $2.98 and its 200 day simple moving average is $4.74. The firm has a market capitalization of $103.44 million, a PE ratio of -1.14 and a beta of 1.56.

Wall Street Analysts Forecast Growth

TNYA has been the topic of several analyst reports. Chardan Capital dropped their price target on shares of Tenaya Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Friday, November 11th. Canaccord Genuity Group initiated coverage on shares of Tenaya Therapeutics in a research note on Monday, November 7th. They set a “buy” rating on the stock. Finally, Canaccord Genuity Group initiated coverage on shares of Tenaya Therapeutics in a research note on Tuesday, November 8th. They set a “buy” rating and a $21.00 price target on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $24.67.

About Tenaya Therapeutics

(Get Rating)

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM).

Further Reading

Want to see what other hedge funds are holding TNYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tenaya Therapeutics, Inc. (NASDAQ:TNYAGet Rating).

Institutional Ownership by Quarter for Tenaya Therapeutics (NASDAQ:TNYA)

Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.